Obstetrics & Gynecology
Professor
Gray CJ Sub-Investigator - Protocol #V503-001: “A Randomized, International, Double-Blinded (With In-House Blinding), Controlled with Gardasil®, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) Virus-Like Particle (VLP) Vaccine Administered to 16-26-Year-Old Women.” Sponsor: Merck & Co. (Principal Investigator: Meera Varman MD) IRB #07-14612 2007-2017
Gray, CJ Sub-Investigator - Protocol #V501 018-10: “A Long Term Immunogenicity, Safety, and Effectiveness Study of Gardasil™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received Gardasil™ at 9-18 Years of Age.” Sponsor: Merck & Co.; (Principal Investigator: Meera Varman, MD) IRB #03-13248
Gray CJ, Sub-Investigator - Protocol #108933 HPV 010: “A phase III-b, Observer-Blind, Randomized Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 Vaccine Versus Merck’s Gardasil® (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine Merck & Co., Inc.) Vaccine When Administered Intramuscularly According to a Three-Dose Schedule in Healthy Adult Females 18-45 Years of Age.” Sponsor: GlaxoSmithKline; (Principal Investigator: Meera Varman, MD) 158,150 IRB #07-14357
Gray CJ, Sub-Investigator - Protocol #104820, Study Coordinator: “A Phase III, Double-Blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-Dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above.” (Product HPV-015) GlaxoSmithKline Biologicals (Principal Investigator: Meera Varman, MD) IRB #05-13928, $24,880
Gray CJ, Sub-Investigator - Protocol #580299/008, Study Coordinator: “A Phase III Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.” (Principal Investigator: Meera Varman, MD) IRB #04-13377, 3,098/subject,
Gray CJ, Principal Investigator*- Treatment of Latent Tuberculosis in Pregnancy, Vice President Health Sciences Health Future Foundation Discretionary Account, IRB #06-14176, $6,000 2007-2011
Gray, CJ. Principal Investigator* - Impact of adding a gynecology service at the Veterans Administration Medical Center on an obstetric and gynecology residency program. 2014
Gray, CJ. Principal Investigator* - Comparison of Interferon Gamma Release Assays and PPD Screening Techniques for Latent Tuberculosis Infection in Pregnant Patients at a Federally Funded Community Health Center 2014
Gray, CJ. Principal Investigator* - Specialty Society Curriculum Affecting CREOG Outcomes. IRB # 11-16083. 2011
Gray, CJ. Principal Investigator*- Comparison of Duramorph and the Q Pain Device in Controlling Postoperative Pain after Cesarean Section, IRB #06-14109. 2005-2012
Gray, CJ. Principal Investigator*- Treatment of Latent Tuberculosis in Pregnancy, IRB #06-14176. 2007-2011
Gray, CJ. Principal Investigator*- Tracking Antepartum and Postpartum Depression Scales in a Resident Clinic Population, IRB#11-16060
Principal Investigator*- Evaluation of the OB/GYN Chief Home Call System at CUMC, IRB #10-15760
Gray, CJ. Principal Investigator*- Cost Analysis of Inpatient Gynecology Consultation: Is an Inpatient Diagnostic Workup Worth the Cost 2010